Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Matheson, Elizabeth C., Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K., Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R., Vormoor, Josef, Irving, Julie A.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717586/
https://www.ncbi.nlm.nih.gov/pubmed/30655370
http://dx.doi.org/10.3324/haematol.2017.185975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717586/
https://www.ncbi.nlm.nih.gov/pubmed/30655370
http://dx.doi.org/10.3324/haematol.2017.185975

Ejemplares similares